S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
AMEX
AIM ImmunoTech Inc (AIM)
AIM ImmunoTech Inc (AIM) News

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:AIM

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
05/20/2024	8:15AM	GlobeNewswire Inc.	AIM ImmunoTech to Participate in Two Upcoming Investor Conferences	AMEX:AIM	AIM ImmunoTech Inc
05/16/2024	6:30AM	GlobeNewswire Inc.	AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update	AMEX:AIM	AIM ImmunoTech Inc
05/15/2024	3:31PM	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:AIM	AIM ImmunoTech Inc
05/09/2024	7:50AM	GlobeNewswire Inc.	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast	AMEX:AIM	AIM ImmunoTech Inc
05/07/2024	7:30AM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:AIM	AIM ImmunoTech Inc
05/07/2024	7:30AM	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:AIM	AIM ImmunoTech Inc
05/06/2024	7:30AM	GlobeNewswire Inc.	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	AMEX:AIM	AIM ImmunoTech Inc
04/29/2024	7:55AM	GlobeNewswire Inc.	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
04/25/2024	7:45AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Release of the Next CEO Corner Segment	AMEX:AIM	AIM ImmunoTech Inc
04/18/2024	7:45AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Release of the Next CEO Corner Segment	AMEX:AIM	AIM ImmunoTech Inc
04/15/2024	7:55AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	AMEX:AIM	AIM ImmunoTech Inc
04/11/2024	10:00AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Release of the Next CEO Corner Segment	AMEX:AIM	AIM ImmunoTech Inc
04/10/2024	7:21AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	AMEX:AIM	AIM ImmunoTech Inc
04/02/2024	6:30AM	GlobeNewswire Inc.	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	AMEX:AIM	AIM ImmunoTech Inc
03/28/2024	7:05AM	GlobeNewswire Inc.	AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference	AMEX:AIM	AIM ImmunoTech Inc
03/26/2024	8:05AM	GlobeNewswire Inc.	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	AMEX:AIM	AIM ImmunoTech Inc
03/25/2024	8:05AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	AMEX:AIM	AIM ImmunoTech Inc
03/22/2024	7:55AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Release of the Next CEO Corner Segment	AMEX:AIM	AIM ImmunoTech Inc
03/20/2024	8:25AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Release of the Next CEO Corner Segment	AMEX:AIM	AIM ImmunoTech Inc
03/15/2024	7:45AM	GlobeNewswire Inc.	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity	AMEX:AIM	AIM ImmunoTech Inc
03/07/2024	7:45AM	GlobeNewswire Inc.	AIM ImmunoTech Announces Launch of CEO Corner Platform	AMEX:AIM	AIM ImmunoTech Inc
02/29/2024	7:45AM	GlobeNewswire Inc.	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update	AMEX:AIM	AIM ImmunoTech Inc
02/21/2024	9:37AM	Edgar (US Regulatory)	Form D/A - Notice of Exempt Offering of Securities: [Amend]	AMEX:AIM	AIM ImmunoTech Inc
02/20/2024	3:34PM	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	AMEX:AIM	AIM ImmunoTech Inc
02/20/2024	3:31PM	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:AIM	AIM ImmunoTech Inc
02/14/2024	7:55AM	GlobeNewswire Inc.	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
02/09/2024	2:47PM	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:AIM	AIM ImmunoTech Inc
02/08/2024	7:50AM	GlobeNewswire Inc.	AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions	AMEX:AIM	AIM ImmunoTech Inc
01/25/2024	4:00PM	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:AIM	AIM ImmunoTech Inc
01/24/2024	8:10AM	GlobeNewswire Inc.	AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc

Showing the most relevant articles for your search:AMEX:AIM

1 2 3 4 5 6 7 8 9 10 Next >>

Saddle Ranch Media (PK)

QED Connect (PK)

Canopus Biopharma (PK)

Nexus Energy Services (PK)

Ronn Motor (PK)

ERHC Energy (CE)

Decentral Life (PK)

Worldwide NFT (CE)

Music Licensing (PK)

Global Developments (PK)

GNCC Capital (CE)

Valiant Eagle (PK)

Lightwave Logic

Bioelectronics (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions